Genetic influence of DPYD*9A polymorphism on plasma levels of 5-fluorouracil and subsequent toxicity after oral administration of capecitabine in colorectal cancer patients of South Indian origin

Author:

Varma Ashok1,Jayanthi Mathaiyan1,Dubashi Biswajit2,Shewade Deepak Gopal1,Sundaram Rajan1

Affiliation:

1. Department of Pharmacology, JIPMER, Puducherry, India

2. Department of Medical Oncology, JIPMER, Puducherry, India

Abstract

AbstractObjectivesHigh interindividual variability was reported with capecitabine toxicities among colorectal cancer (CRC) patients. DPYD*9A polymorphism was reported responsible for grade 3 or 4 toxicities. Finding the phenotypic association between DPYD*9A polymorphism and 5-fluorouracil (5-FU) plasma levels will give a better prediction for toxicity susceptibility.MethodsA total of 145 CRC patients were included in the final analysis. Each patient received capecitabine of 1,000 mg/m2 twice daily for the first 14 days of a 21 day cycle. 5-FU levels were measured at two-time points 2 and 3 h post capecitabine administration across the 1st and 4th cycles of chemotherapy. 5-FU levels were measured using liquid chromatography and tandem mass spectrometry (LC-MS/MS). Genotyping analysis was done by real-time PCR (RT-PCR).ResultsThe mean 5-FU drug levels measured during the 1st cycle at time points 2 and 3 h were found to be 267 ng/mL ± (29) and 124 ng/mL ± (22) respectively. Whereas, the observed 5-FU levels in the 4th cycle were 275 ng/mL ± (28) and 130 ng/mL ± (26) respectively. Patients with 5-FU levels in the range of 281–320 and 141–160 ng/mL at 2 and 3 h respectively showed a higher risk for the hand-foot syndrome (HFS) and thrombocytopenia. No association was found between DPYD*9A polymorphism and 5-FU drug levels measured at time point 2 h across both the cycles. However, the drug levels measured at 3 h were found to be significantly different across the DPYD*9A genotypes. Individuals with GG genotype showed significantly higher 5-FU levels when compared to AA genotype.ConclusionsDPYD*9A polymorphism had a significant influence on the plasma levels of 5-FU after capecitabine administration. The 5-FU levels measured at 3 h corresponding to elimination t1/2 was significantly higher in patients with GG genotype compared AA genotype.

Funder

JIPMER

Publisher

Walter de Gruyter GmbH

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics

Reference42 articles.

1. Genotype frequencies of drug-metabolizing enzymes responsible for purine and pyrimidine antagonists in a healthy Asian-Indian population;Biochem Genet,2012

2. New advances in DPYD genotype and risk of severe toxicity under capecitabine;PloS One,2017

3. Simple determination of capecitabine and its metabolites by liquid chromatography with ultraviolet detection in a single injection;J Chromatogr B Analyt Technol Biomed Life Sci,2004

4. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update;Ann Oncol,2017

5. New advances in DPYD genotype and risk of severe toxicity under capecitabine;PloS One,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3